To include your compound in the COVID-19 Resource Center, submit it here.

Basal insulin peglispro: Phase III data

Top-line data from the 78-week, open-label, international Phase III IMAGINE-1 trial in 455 Type I diabetics showed that once-daily subcutaneous basal insulin peglispro met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 26. Eli Lilly

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers